Treatment Set TS331802 is a Intradermal; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Antigen Laboratories, Inc.. The primary component is Aspergillus Fumigatus; Alternaria Alternata; Juglans Nigra Pollen; Populus Deltoides Pollen; Quercus Alba Pollen; Ambrosia Artemisiifolia Pollen; Salsola Kali Pollen.
| Product ID | 49288-0686_89f9e682-acd9-4cc7-982d-c32f69b33b07 |
| NDC | 49288-0686 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Treatment Set TS331802 |
| Generic Name | Treatment Set Ts331802 |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRADERMAL; SUBCUTANEOUS |
| Marketing Start Date | 1986-10-31 |
| Marketing Category | BLA / BLA |
| Application Number | BLA102223 |
| Labeler Name | Antigen Laboratories, Inc. |
| Substance Name | ASPERGILLUS FUMIGATUS; ALTERNARIA ALTERNATA; JUGLANS NIGRA POLLEN; POPULUS DELTOIDES POLLEN; QUERCUS ALBA POLLEN; AMBROSIA ARTEMISIIFOLIA POLLEN; SALSOLA KALI POLLEN |
| Active Ingredient Strength | 0 g/mL; g/mL; g/mL; g/mL; g/mL; [AU]/mL; g/mL |
| Pharm Classes | Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS] |
| NDC Exclude Flag | E |
| Listing Certified Through | 2017-12-31 |
| Marketing Start Date | 1986-10-31 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA102223 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1986-10-31 |
| Inactivation Date | 2019-10-21 |
| Ingredient | Strength |
|---|---|
| ASPERGILLUS FUMIGATUS | .005 g/mL |